[Treatment concepts for primary oligometastatic prostate cancer].

CONCLUSIONS: In the current guidelines, systematic therapy is standard of care in mHSPC patients. In patients with low metastatic burden, a survival benefit was observed when adding percutaneous RT to the prostate. Retrospective studies also suggest a benefit when adding RP. However, whether MDT prolongs survival is still unknown.
PMID: 32274541 [PubMed - as supplied by publisher]

Source: Der Urologe. Ausg. A - April 8, 2020 Category: Urology & Nephrology Authors: Knipper S, Graefen M, Hadaschik B, Wiegel T Tags: Urologe A Source Type: research